P-273 Concordance of RAS mutation status in CRC patients by comparison of results from circulating tumour DNA and tissue-based testing
Rodney J. Scott(New South Wales Department of Health), Stephen B. Fox(Peter MacCallum Cancer Centre), Peter Pockney(Hunter Medical Research Institute), Kateh Namdarian(The University of Melbourne), Brian Draganic(John Hunter Hospital), Danilo Acosta(The University of Melbourne), Frederick S. Jones(Sysmex (Japan)), Amanda Lucas(The University of Melbourne), Timmy Chan(The University of Melbourne), SorWay Chan(Peter MacCallum Cancer Centre), Chelsee Hewitt(St. Mary's Hospital), Hazel Phillimore(Peter MacCallum Cancer Centre), S Dooley(John Hunter Hospital), Cliff Meldrum(New South Wales Department of Health), William F. Lewis, E. Shi(The University of Melbourne)
Cited by 1
Related Papers
Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome
|Clinical Cancer Research|2008|1.5k
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study
|The Lancet Oncology|2012|1.3k
<i>BRCA</i> Mutation Frequency and Patterns of Treatment Response in <i>BRCA</i> Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group
|Journal of Clinical Oncology|2012|1.2k
The 2019 World Health Organization classification of tumours of the breast
|Histopathology|2020|1.1k
Inflammatory subtypes in asthma: Assessment and identification using induced sputum
|Respirology|2006|939